Combining Immunocytokine and Ex Vivo Activated NK Cells as a Platform for Enhancing Graft-Versus-Tumor Effects Against GD2+ Murine Neuroblastoma

Combining Immunocytokine and Ex Vivo Activated NK Cells as a Platform for Enhancing Graft-Versus-Tumor Effects Against GD2+ Murine Neuroblastoma

Management for high-risk neuroblastoma (NBL) has included autologous hematopoietic stem cell transplant (HSCT) and anti-GD2 immunotherapy, but survival remains around 50%. The aim of this study was to determine if allogeneic HSCT could serve as a platform for inducing a graft-versus-tumor (GVT) effe...

Full description

Bibliographic Details
Main Authors: Paul D. Bates, Alexander L. Rakhmilevich, Monica M. Cho, Myriam N. Bouchlaka, Seema L. Rao, Joanna M. Hales, Rimas J. Orentas, Terry J. Fry, Stephen D. Gilles, Paul M. Sondel, Christian M. Capitini
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-08-01
Series:Frontiers in Immunology
Subjects:
immunocytokine
NK cells
neuroblastoma
graft-versus-tumor effect
cytokine release syndrome
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2021.668307/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2021.668307/full

Similar Items